Xi I Chen

20120059548, Mar 8, 2012

Aug 31, 2011

13/222437

Sunil K. Agrawal - Newark DE, US
James C. Galloway - Elkton MD, US
Xi Chen - Newark DE, US
Christina B. Ragonesi - Newark DE, US
Sherry Liang - Staten Island NY, US
Stephen Dolph - New Carlisle IN, US
Zachary R. Schoepflin - Centerport NY, US

University of Delaware - Newark DE

G05D 1/00
B62D 6/00
G06F 19/00

701 41, 701 1, 701 93

Powered mobility systems and methods are disclosed. A powered mobility system includes a mobile unit, a support frame, a plurality of markers, a motion capture device, and a processor. The mobile unit is operable to move the powered mobility system. The support frame is adapted to support a user. The plurality of markers are configured to be attached to the user. The motion capture device is configured to detect movement of the plurality of markers. The processor is programmed to receive signals from the motion capture device, translate the signals into instructions for moving the mobile unit, and transmit the instructions to the mobile unit. A powered mobility method includes placing a user in a support frame, attaching a plurality of markers to the user, detecting movement of the plurality of the markers, and generating movement of the mobile unit based on the movement of the plurality of the markers.

20220370810, Nov 24, 2022

Mar 2, 2022

17/684969

- Sylmar CA, US
Xi Lin Chen - Stevenson Ranch CA, US
Xiyao Xin - Northridge CA, US
Xin Huang - Fremont CA, US

Pacesetter, Inc. - Sylmar CA

A61N 1/372
A61N 1/375
A61N 1/39
A61N 1/378

Certain embodiments described herein related to methods, devices, and systems that provide improved communications between first and second IMDs remotely located relative to one another and capable of communicating using both conductive communication and RF communication. Such a method can include the first IMD using conductive communication to transmit message(s) intended for the second IMD, without using RF communication, during a first period of time that a first trigger event is not detected. The method can also include the first IMD detecting the first trigger event, and in response thereto, the first IMD using RF communication to transmit message(s) intended for the second IMD during a second period of time. Thereafter, in response to first IMD detecting a second trigger event, the first IMD uses conductive communication to transmit one or more messages intended for the second IMD, without using RF communication, during a third period of time.

20220338809, Oct 27, 2022

Feb 11, 2022

17/669968

- Sylmar CA, US
Yash Vardhan Tiwari - Valencia CA, US
Xi Lin Chen - Stevenson Ranch CA, US
Xiyao Xin - North Ridge CA, US

A61B 5/00
A61B 5/024
A61B 5/055
A61B 5/07

An implantable medical device (IMD) is provided and includes sensing circuitry coupled to electrodes. The sensing circuitry is configured to sense electrical biological signals indicative of a non-physiologic condition of interest experienced by a patient during a magnetic resonance imaging (MRI) procedure, and in the presence of an MRI scanning sequence, the MRI scanning sequence includes at least one of radio frequency (RF) or gradient fields that are in an active state for active field intervals. The device includes memory to store the biological signals and to store program instructions and includes a processor that, when executing the program instructions, is configured to: determine start times for the active field intervals when the at least one of RF or gradient fields switch to the active state and manage generation of MRI-induced-noise corrected (MRI-INC) biological signals, based on the start times for the active field intervals, by at least one of: 1) applying a blanking interval to the sensing circuitry to blank a sensing operation during at least portions of the active field interval or 2) modifying segments of the biological signal sensed during at least the portions of the active field interval, and 3) comparing biologic signal sensed during at least the portions of the active field interval to a template. The device analyzes the biological signals for an indication that the patient is experiencing the non-physiologic condition.

20220339452, Oct 27, 2022

Feb 11, 2022

17/670005

- Sylmar CA, US
Xi Lin Chen - Stevenson Ranch CA, US
Xiyao Xin - Northridge CA, US
Yash Vardhan Tiwari - Valencia CA, US

A61N 1/37
G01R 33/28
G01R 33/34
A61B 5/33
A61B 5/29
A61N 1/372
A61N 1/365

An implantable medical device (IMD) includes electronic circuitry, and one or more processors configured to switch operation of a first coil of the electronic circuitry between the first and second modes. When in the first mode, the one or more processors are configured to manage operation of the electronic circuitry and the first coil to at least one of sense biological signals, deliver treatment for a non-physiologic condition, or wirelessly communicate with at least one of an external device or second implanted device. When in the second mode, the one or more processors are configured to manage operation of the electronic circuitry and the first coil to detect the time varying MR generated gradient field along the first axis.

20170007712, Jan 12, 2017

Aug 1, 2016

15/225819

- Bagsvaerd, DK
David A. Zopf - Wayne PA, US
Robert J. Bayer - San Diego CA, US
David Hakes - Willow Grove PA, US
Caryn L. Bowe - Doylestown PA, US
Xi Chen - Lansdale PA, US

Novo Nordisk A/S - Bagsvaerd

A61K 47/48
A61K 38/18
A61K 38/48
A61K 38/24
C12N 9/72
A61K 38/21
A61K 38/40
C12N 9/96
C12N 9/64
C07K 16/24
A61K 38/19

The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

20160338624, Nov 24, 2016

May 18, 2015

14/715385

- Sylmar CA, US
Xi Lin Chen - Valencia CA, US

A61B 5/1473
A61B 5/00
A61B 5/145

In accordance with one embodiment, a blood glucose sensing device is provided that comprises a house having of an exterior surface and that defines an interior space. The housing is configured to be located within a cardiovascular pathway of a patient. An inductor-capacitor (LC) circuit is located within the interior space defined by the housing. The inductor-capacitor circuit comprises an inductive circuit and a capacitive circuit electronically coupled to one another. The inductive and capacitive circuit has inductance and capacitance values that define a blood glucose sensitive resonant frequency such that a resonant frequency of the LC resonant circuit varies in response to changes in blood glucose levels within the blood in the cardiovascular pathway surrounding the housing.

20160338625, Nov 24, 2016

May 18, 2015

14/715390

- Sylmar CA, US
Xi Lin Chen - Valencia CA, US

A61B 5/1473
A61B 5/00
A61B 5/145

A blood glucose sensing device is provided that comprises a house having an exterior surface and that defines an interior space. The housing is configures to be located within a cardiovascular pathway of a patient. A resonant antenna is located within the interior space defined by the housing. The resonant antenna comprises an inductive reactance and a capacitive reactance. The inductive and capacitive reactance have values that define a blood glucose sensitive resonant frequency such that a resonant frequency of the resonant antenna varies in response to changes in blood glucose levels within the blood in the cardiovascular pathway surrounding the housing.

20160200795, Jul 14, 2016

Dec 18, 2015

14/974841

- Bagsvaerd, DK
David A. Zopf - Wayne PA, US
Robert J. Bayer - San Diego CA, US
Caryn Bowe - Doylestown PA, US
David James Hakes - Willow Grove PA, US
Xi Chen - Lansdale PA, US

Novo Nordisk A/S - Bagsvaerd

C07K 14/755
A61K 47/48
A61K 38/37
C07K 1/107

The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.